O’Melveny represented China International Capital Corporation Hong Kong Securities Limited as the sole sponsor and overall coordinator in the IPO. Qyuns Therapeutics Co., Ltd. (2509.HK) announced...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised the underwriters on the deal while O’Melveny represented OrbusNeich Medical Group. OrbusNeich Medical Group Holdings Limited (6929.HK) announced its approximate US$61.6 million (approximately HK$481...
You must be a Standard 1 Year member to access this content.
Herbert Smith Freehills advised CICC and CSCI on the deal while O’Melveny recently represented 3D Medicines. CICC and CSCI acted as joint sponsors of 3D Medicines...
You must be a Standard 1 Year member to access this content.
Sidley represented Lushang Life Services Co., Ltd. on the deal while O’Melveny advised ABCI Capital Limited and China International Capital Corporation Hong Kong Securities Limited. Lushang...
You must be a Standard 1 Year member to access this content.
Harneys, Tian Yuan Law Firm LLC, and O’Melveny & Myers LLP acted for Gushengtang Holding Limited. Linklaters and Zhong Lun Law Firm assisted the joint sponsors....
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers and Cooley LLP advised Keymed Biosciences Inc. on the deal, while Kirkland & Ellis advised the joint sponsors and underwriters. Keymed Biosciences Inc....
You must be a Standard 1 Year member to access this content.
